Last reviewed · How we verify
Mesenchymal progenitor cells
Mesenchymal progenitor cells is a Biologic drug developed by Shanghai AbelZeta Ltd.. It is currently in Phase 2 development.
Mesenchymal progenitor cells have been studied in various conditions, including Lupus Erythematosus, Anterior Cruciate Ligament Injury, Osteoarthritis, Spinal Cord Injury, and Acute Kidney Injury, through interventions such as secretome and MSB-CAR001 Combined With Hyaluronan. The mechanism of action of mesenchymal progenitor cells is classified as somatic cell supplemental therapy, according to ChEMBL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mesenchymal progenitor cells |
|---|---|
| Sponsor | Shanghai AbelZeta Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD (NA)
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- cfMSC Therapy for Diabetes (PHASE1, PHASE2)
- Exosomes Effect on Visual Function in CVI
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- cfMSC Stem Cell Therapy Targeting COPD (PHASE1, PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesenchymal progenitor cells CI brief — competitive landscape report
- Mesenchymal progenitor cells updates RSS · CI watch RSS
- Shanghai AbelZeta Ltd. portfolio CI
Frequently asked questions about Mesenchymal progenitor cells
What is Mesenchymal progenitor cells?
Who makes Mesenchymal progenitor cells?
What development phase is Mesenchymal progenitor cells in?
Related
- Manufacturer: Shanghai AbelZeta Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing